Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2008 1
2009 2
2010 5
2011 3
2012 2
2013 1
2015 3
2016 11
2017 15
2018 13
2019 10
2020 8
2021 13
2022 6
Text availability
Article attribute
Article type
Publication date

Search Results

77 results
Results by year
Filters applied: . Clear all
Page 1
Druggable cancer phosphatases.
Vainonen JP, Momeny M, Westermarck J. Vainonen JP, et al. Among authors: momeny m. Sci Transl Med. 2021 Apr 7;13(588):eabe2967. doi: 10.1126/scitranslmed.abe2967. Sci Transl Med. 2021. PMID: 33827975 Review.
PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells.
Kauko O, O'Connor CM, Kulesskiy E, Sangodkar J, Aakula A, Izadmehr S, Yetukuri L, Yadav B, Padzik A, Laajala TD, Haapaniemi P, Momeny M, Varila T, Ohlmeyer M, Aittokallio T, Wennerberg K, Narla G, Westermarck J. Kauko O, et al. Among authors: momeny m. Sci Transl Med. 2018 Jul 18;10(450):eaaq1093. doi: 10.1126/scitranslmed.aaq1093. Sci Transl Med. 2018. PMID: 30021885 Free PMC article.
Cancer stem cell phosphatases.
Momeny M, Arsiola T, Westermarck J. Momeny M, et al. Biochem J. 2021 Jul 30;478(14):2899-2920. doi: 10.1042/BCJ20210254. Biochem J. 2021. PMID: 34319405 Review.
77 results